Categories: HealthcareNews

Radiation Shield Technologies Sets new Industry Standards with ISO 9001:2015 Certification for Demron Products”

MIAMI, Nov. 14, 2024 /PRNewswire/ — Radiation Shield Technologies (RST), a leader in advanced personal protection systems, proudly announces that its Demron product line has been awarded the ISO 9001:2015 Certification. This certification underscores RST’s commitment to superior quality management and continuous improvement in its production processes. ISO 9001:2015 is an international standard for quality management systems and provides a framework for organizations to ensure consistent product and service quality, improve processes, and enhance customer service satisfaction.

Demron, is known for its advanced and innovative radiation chemical, biological and heat stress protection capabilities and is used world wide used by Military, Emergency Services, Healthcare Professionals, and various Government entities globally. RSTs Demron products have been tested in numerous national laboratories and by government agencies such as NASA and the DOE. Demron has been field tested by multiple government branches and featured in a multitude of scientific journals, receiving global media coverage from major news networks. 

The ISO 9001:2015 Certification affirms RST’s dedication to delivering reliable, high-quality protective gear meeting international standards. 

Please visit our website at https://www.radshield.com/.

View original content to download multimedia:https://www.prnewswire.com/news-releases/radiation-shield-technologies-sets-new-industry-standards-with-iso-90012015-certification-for-demron-products-302305124.html

SOURCE Radiation Shield Technologies

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

26 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

26 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

3 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

4 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

18 hours ago